Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
More recently, an agent which targets both GLP-1 and GIP receptors (tirzepatide) received regulatory clearance for treatment of type 2 diabetes
In the landmark study that introduced it, published in Cell Metabolism (Lee et al., 2015), researchers showed that MOTS-c regulates insulin sensitivity and metabolic homeostasis through the AMPK pathway, and that treatment prevented diet-induced obesity and insulin resistance in animal models
If you are unsure whether you fall into a highrisk group, read our detailed guide on who should avoid GLP1 medications before starting any injection: Who should not take GLP1 drugs
Healthcare providers monitor patient response at this dose level for at least 4 weeks before considering any adjustments
